Research Article

Complementary and Integrative Approaches to Cancer: A Pilot Survey of Attitudes and Habits among Cancer Patients in Italy

Massimo Bonucci, Andrea Geraci, Dina Pero, Cristina Villivà, Daniele Cordella, Maria Condello, Stefania Meschini, Laura del Campo, Franco Tomassi, Alessandro Porcu, Francesco De Lorenzo, and Francesco Lozupone

1 Association for Research on Integrative Oncological Therapies (ARTOI), Roma, Italy
2 Italian Center for Global Health, Istituto Superiore di Sanità, Roma, Italy
3 Italian Association for Cancer Patients, Relatives and Friends (AIMaC), Roma, Italy
4 Directorate-General Information Technology Unit, Istituto Superiore di Sanità, Roma, Italy
5 National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma, Italy

Correspondence should be addressed to Francesco Lozupone; francesco.lozupone@iss.it

Received 29 December 2021; Accepted 27 May 2022; Published 1 August 2022

Academic Editor: Talha Bin Emran

Copyright © 2022 Massimo Bonucci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Cancer patients are among the main consumers of traditional, complementary, integrative, and alternative medicine (TCIM) such as natural products (herbals, integrators, etc.) and mind and body practices (yoga, acupuncture, etc.). Methods. A questionnaire on TCIM was submitted to 415 Italian cancer patients. The questionnaire consisted of three sections: (i) biographical and clinical information; (ii) use of natural substances; and (iii) use of mind-body practices. Results. 406 patients completed the questionnaire. The prevalence of TCIM use was 72.3%. Of them, 75.6% started to use TCIM after a tumor diagnosis. The main reasons for using TCIM were to mitigate side effects (65.0%), to regain physical and mental balance (35.9%), to relieve pain (18.3%), and to improve the efficacy of cancer therapy (16.0%). 44.7% of patients taking natural products used them during conventional therapies (chemotherapy, radiotherapy, etc.), and in 67.5% of cases without consulting a doctor. As a consequence, only about 50% of patients taking natural substances used these compounds appropriately, and the most common errors were related with the purpose of reducing the side effects of the therapy (52.3%) and for boosting immune system (32.1%). Conclusions. There is an impelling need to provide patients with scientifically validated information to raise awareness about the benefits and risks of using TCIM.

1. Introduction

According to the International Agency of Research on Cancer (IARC), 1 in 5 people in the world will develop cancer in their lifetime, and about 8% women and 12% men die from this pathology. Breast cancer is the most commonly diagnosed cancer (6.9%), and together with lung cancer it remains the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), and stomach (7.7%) [1]. Although in the last years early detection and effective treatments have reduced mortality rates, they remain high, particularly in low-income countries [2, 3]. Moreover, cancer therapies are often accompanied by severe side effects that not only affect the quality of life, but can also lead to more suffering and to a reduced response to treatments [4, 5]. This is why an increasing number of patients is turning to unconventional approaches, i.e., complementary medicines, hoping to improve the outcomes [6–9].

The World Health Organization (WHO) defines complementary medicine as “a set of health practices that are not part of a country’s tradition or conventional medicine and are not fully integrated into the dominant health system.” In 2017, the WHO unit of traditional and complementary...
Evidence-Based Complementary and Alternative Medicine

2 Methods

2.1 Data Sources and Patients Setting. A descriptive cross-sectional survey was conducted between April 2018 and May 2019 to collect data on cancer patients’ choices of TCIM. Patients were asked to complete the questionnaire using the online form, available on the web portals of the Italian Institute of Health, AIMaC and ARTOI websites, or the paper form, offered to patients at the AIMaC and ARTOI information points, located in the main oncologic hospitals and in the waiting rooms of the oncologists who kindly participated in the project. All papers and electronic questionnaires collected were returned to the investigators and then the data were coded for analysis, in compliance with EU Regulation 2016/679 established by the European Parliament and Council on April 27, 2016 for the protection of individuals, with particular regard to the processing of personal data and the free movement of such data. Patients completed the questionnaire anonymously, and without assistance.

Patients’ participation was on a voluntary basis and did not interfere with their medical treatment. All participating patients received information about the study. Patients were considered eligible if they met the following inclusion criteria: they were Italian-speaking over 18 years of age, without distinction of gender, diagnosed with cancer, aware of their diagnosis, able to understand the questions, and free from any condition that made filling out the questionnaire inappropriate or burdensome for the patients themselves. This survey was approved by the Ethics Committee of the Italian National Institute of Health.

2.2 The Questionnaire. The questionnaire used for the survey consists of three sections: the first section concerns personal and clinical information, including demographic (age and sex) and clinical data (location of primary tumor, time since diagnosis, position in the cancer treatment pathway, and drugs received); the second section concerns the use of biological products (BP) such as vitamins and minerals, herbal and probiotics products etc., which of them was used, when they were taken (before, during, or after therapy), for how long, how often and for what purpose, who suggested them, whether or not the choice was discussed with an oncologist or health specialists and, finally, whether they had any benefit; the third section concerns MBP and follows the same criteria as the previous one. Some products that may also be routinely prescribed medical therapies, such as iron, vitamin D, and calcium supplements, were included in the BP analysis. The online questionnaire was developed using “in-house” software developed by Daniele Cordella as the SurveyPro module of the Open Source Moodle application (https://www.moodle.org) available from (https://github.com/moodle/moodle). It can be downloaded freely from GitHub at https://github.com/kordan/moodle-mod_surveypro.

2.3 Data Analysis. The median, range, and relative frequencies were used in the descriptive analysis. Frequency analyses and cross tables with χ² tests were performed. Only the questionnaires for which at least the first section was completed were analyzed. A cut-off value of p < 0.05 was used. No differences were observed between data collected using online or paper questionnaires.
3. Results

3.1. Patients’ Characteristics. 415 patients agreed to participate in this survey. Only questionnaires in which at least the first section was completed were considered analyzable, therefore, we then evaluated the responses of 406 of the 415 patients. 76.8% of patients were women, with a median age of 56 (range 24–84), 23.2% were men with a median age of 62 years (20–93). The most frequent site of primary tumor was the breast (47.8%), followed by gastrointestinal cancers (12.3%), hematological cancers (5.7%), hepato-pancreatic-biliary tumors (5.7%), and cervical and lung tumors (3.9%) each (Figure 1).

Out of 406 patients that completed the questionnaire, 116 patients (28.6%) reported not using TCIM, 228 (56.2%) used BP, 192 (47.0%) used MBP, and 30.3% used both. Patient’s therapy phases (before, during, and after therapy) and therapy categories (neoadjuvant, adjuvant, and exclusive) are shown in Table 1.

3.2. Analysis of Patients’ Responses about TCIM Choices. As detailed in Table 2, the BP most commonly reported by patients were salts and micronutrients (40.8%), vitamins (36.0%), turmeric and curcumin-based products (35.1%), aloë extracts 13.6%, mushrooms from traditional Chinese medicine (12.7%), homeopathic products (9.6%), probiotic and polydatin (8.8%), indole-3-carbinol, and sulforaphane (7.0%). 17% of patients were taking various commercially available compounds. The most commonly used MBP were “massages and manual care” (63.4% of patients), with psychic and spiritual treatments (meditation, music and art therapy, mindfulness, etc.) (33.5%), yoga (23.6%), acupuncture (20.4%), osteopathic medicine (15.2%), reiki (14.1%), Qi gong/Tai Chi (12.6%), light sports practices, (6.8%), etc. 80.7% of patients taking BP reported taking more than one product, while more than one MBP was chosen by 41.9% patients using MBP.

When and why did patients try TCIM approaches? As shown in Table 3, more than 70% of the patients who responded to the questionnaire stated that started using TCIM immediately after diagnosis (71.1% and 79.1% for BP and MBP, respectively), and almost half of them were taking TCIM during conventional therapy (44.3% and 31.4% for BP and MBP users, respectively). Although no statistically significant differences were noted between BP and MBP users before diagnosis and therapy (not shown), the number of patients using MBP was significantly lower than that of BP patients (31.4% vs. 44.3%, p < 0.01). Such differences increased significantly after therapy (37.2% vs. 20.6% of patients taking BP, p < 0.01). Overall, 71.9% of patients responded to the questionnaire stated that started using MBP, while it was slightly higher, but not statistically significant, the percentage of patients who stated to practice habitually MBP (75.9%, p = 0.829448) (Figure 2).

The most common motivations for the use of BP were (multiple responses were allowed): improving the immune system (66.2%), mitigating side effects (44.7%), and improving the impact of cancer therapy (26.3%) (Figure 3, black bars). Regarding the choice to use MBP, the main reason was the need to regain physical and mental balance (75.9%), followed by mitigating the side effects of conventional therapy (27.2%) and relieving pain (17.3%) (Figure 3, grey bars). No significant differences were observed between the responses of women and men.

As for the process that led patients to choose the BP or MBP approaches, in our study 11.0% of BP patients and 28.3% of MBP patients made their choice on their own without consulting anyone. To these, it should be added the percentage of those who obtained information from social media or magazines (9.2 and 6.8 for BP and MBP patients, respectively), relatives, friends (24.0% and 20.9% for BP and MBP patients, respectively). However, among those taking BP, the oncologist was the main consultant (32.0%), followed by the family doctor (12.7%) and by the dietician/nutritionist (11.0%) (Table 4 left columns). In addition, 22.3% of patients who learned from unverifiable sources, did not inform their oncologist or family doctor, and 39.2% of them reported to take BP during therapy.

As regards to patients using MBP, the sources of information were healthcare professionals (29.4%), personal decision (28.3%), relative or friends (20.9%), patients’ associations (11.5%), other patients (6.8%), etc. (Table 4 right columns).

Afterwards, when asked if they perceived any benefit, 90.6% of patients who made use of MBP answered in the affirmative (Figure 4(a)), while this percentage decreased significantly among patients who took BP (48.2%), and 33.3% of them did not answer (Figure 4(b)).

Finally, we compared the patients’ responses on why they had taken one or more BP with the actual properties and toxicokinetic characteristics of the same products accepted by the competent body or in the scientific
Table 1: TCIM and therapy phases of patients.

| Therapy phase                              | BP  | MBP | Both | No. of TCIM taking patients |
|--------------------------------------------|-----|-----|------|-----------------------------|
| **A** Distribution of TCIM users (n = 296) | n   | %   | n    | %   | n    | %   | n    | %   | n    | %   | n    | %   |
| Distribution of TCIM users                 | 228 | 56.2| 191  | 47.0| 123  | 30.0| 116  | 28.6|
| **Before therapy**                         |     |     |      |     |      |     |      |     |
| Total                                      | 22  | 9.6 | 11   | 5.8 | 5    | 4.1 | 20   | 17.2|
| Waiting for the therapy                    | 0.0 | 0.0 | 4    | 36.4| 11   | 55.0|
| I was excised/I will undergo surgery       | 0.0 | 0.0 | 7    | 63.6| 9    | 45.0|
| Total                                      | 104 | 45.6| 62   | 32.5| 49   | 39.8| 52   | 44.8|
| **In therapy**                             |     |     |      |     |      |     |      |     |
| Neoadjuvant                                | 17  | 6.35| 6    | 9.7 | 11   | 21.2|
| Adjuvant therapy                           | 57  | 54.8| 42   | 67.7| 29   | 55.8|
| Exclusive therapy                          | 21  | 20.2| 9    | 14.5| 10   | 19.2|
| Not specified                              | 9   | 8.7 | 5    | 8.1 | 2    | 3.8 |
| Total                                      | 75  | 32.9| 92   | 48.2| 50   | 40.7| 31   | 26.7|
| **After the therapy**                      |     |     |      |     |      |     |      |     |
| Follow-up                                  | 0.0 | 0.0 | 52   | 56.5| 23   | 74.2|
| long-term survivor                         | 0.0 | 0.0 | 40   | 43.5| 8    | 25.8|
| Palliative therapy and pain management     | 6   | 22.2| 7    | 3.7 | 3    | 2.4 | 6    | 5.2 |
| **Refused the therapy**                    |     |     |      |     |      |     |      |     |
| Not specified or not known                 | 5   | 23.8| 5    | 2.1 | 4    | 3.3 | 1    | 0.1 |
|                                          | 16  | 7.0 | 15   | 7.9 | 12   | 9.8 | 6    | 5.2 |

(A) Distribution of BP patients, MBP patients, or patients using both approaches, (left columns), compared to patients not taking TCIM (right columns). (B) Patients taking TCIM in relation to stage of therapy. TCIM: Traditional Complementary Integrative Medicine; BP, herbs integrators nutraceuticals, food supplements, etc.; MBP: mind-body practices.
literature (preclinical and clinical evidences). As shown in Table 5, less than half of the BP taking patients used these compounds appropriately. 25.5% of patients chose BP for purposes not related to the actual features of the product taken, and a further 25.9% of patients took more than one product, but only some of them were correctly taken. The
The most common errors were found in the use of supplements to reduce the side effects of therapy (52.3%), to support the immune system (32.1%), to reinforce conventional therapies (37.3%), and 8 out of 11 patients who used BP to reduce pain used products that do not possess these properties (Table 6).

Figure 3: Patients’ motivations for using TCIM among BP users (black bars) or MBP users (grey bars). Multiple responses were allowed.

Figure 4: Personal experience with TCIMs. Rate of patients and perception of benefits by patients taking BP (a) and patients taking MBP (b).
4. Discussion

Traditional complementary and integrative medicines are an important health resource, often underestimated, but considered by an increasing number of patients. In this study, we started a survey about the use of TCIMs by cancer patients with the aim of (i) assessing the use of these products in relation to disease stage and suggested therapies and (ii) analyzing how BP or MBP were chosen in relation to cancer therapies, to highlight the potential risks from harmful combinations.

As previously reported [8, 28–30], the BP mentioned most frequently used products by patients were herbals, accounting for almost 40% of the products, followed by vitamins, salts, and minerals. The most commonly used herbals were curcumin and aloe products, both of which were among the best-known herbal remedies with healing or soothing properties. Among MBPs, massage and manual care appear to be the most commonly used practices (63.4%), followed by mind and body practices (33.5%), yoga (23.6%), and acupuncture (20.4%) (Table 2).

An essential aspect that emerges from this survey is that patients begin to turn their attention to BP after a cancer diagnosis (more than 80% of interviewed patients), as already highlighted in several articles [6, 9, 31–35]. More importantly, nearly half of the patients said that they started taking BP while they were in therapy. In general, BP use seems to be more common among patients at an early stage of the disease (0–1 years after diagnosis), (36.0% and 21.6% for BP and MBP using patients, respectively). In contrast, MBPs were more common among patients in follow-up and long-term survivors (47.9% vs. 30.7% of BP), suggesting that their choice might be related to a different way of viewing life after the cancer experience, or after the acute phase of their disease.

The main reasons of BP choices were to support the immune system (66.2%), which is often severely compromised by chemotherapy, and to reduce the side effects of chemotherapy (44.7%). As for the MBP, the main reasons were the search for psycho-health balance (75.9% of patients), understandably destabilized by the disease, to counteract the toxic effects of chemotherapy (27.2%) and to relieve pain (17.3%). In general, it can be deduced that the reasons for the complementary choices lie in the desire to achieve holistic well-being, and to optimize the therapeutic effect of conventional therapy, which can also be severely compromised by dramatic side effects, such as cachexia and chronic inflammation induced by chemotherapy, which itself can lead to severe morbidity and to a significantly increased mortality [4, 36, 37].

Another important issue that we tried to address was the source of information and how TCIM choices were discussed with the family doctor or the oncologist. As described in similar studies, more than half of the patients (53.9% of BP and 73.4% of MBP users) learned about TCIM from uncontrollable or nonprofessional sources, which cannot always guarantee correct information. In addition, approximately one third of the patients interviewed did not inform the oncologist or family doctor about the products they were taking [14, 38]. The issue of self-selected products should not be undervalued, herbal remedies in special way, are considered natural, and erroneously safe, underestimating the effects of drug/BP interactions that can seriously compromise the efficacy of the therapy or increase its toxicity [20, 39, 40]. To this end, patients’ responses on their motivation to take a specific BP were compared with the actual properties and toxicological characteristics of the same product (according to scientific literature and or official reports from institutional sites). Our analysis suggested that almost half of the BPs taking patients used BPs

| Intended use (% of patients) | Unproperly taken for the intended use | Total |
|-----------------------------|-------------------------------------|-------|
|                             | n        | %     | n     | %     |
| Boost immune system/immune response | 43/134 | 32.1 | 134 | 58.8 |
| Reduce/alleviate side effects of the therapy | 46/88 | 52.3 | 88 | 38.6 |
| Strengthen effects of the therapy | 22/59 | 37.3 | 59 | 25.9 |
| Reduce/alleviate pain | 8/11 | 72.7 | 11 | 4.8 |
| Others | 8/24 | 33.3 | 24 | 10.5 |
| Instead of therapy | 4/4 | 100.0 | 4 | 1.8 |

Distribution of accuracy of BP-intended use among BP users (patients could indicate more than one reason).
improperly, as detailed in Table 5, 25.9% of patients chose BPs for purposes not attributable to the product they were taking, and 25.9% of patients took more than one product, but only some of them were correctly chosen. The most common errors were related to the hope of increasing chemotherapy efficacy and reducing side effects, particularly those related to a weakened immune system (Table 6).

To highlight the importance of correct information and the risks that patients run with the use of BPs, we would like to illustrate two examples taken from the questionnaire.

A 48-year-old breast cancer patient said that during the therapy with letrozole and triptorelin, an effective therapy for most hormone-sensitive cancers [41], she had taken mistletoe and nux-vomica of her own accord, to increase the effectiveness of the therapy. As well known, letrozole is metabolized by the CYP450 CYP3A4 and CYP2A6 isoenzymes. Although mistletoe appears to be effective in improving the quality of life of breast cancer patients during chemotherapy and follow-up [42, 43], the fact that raw mistletoe contains toxic constituents cannot be overlooked; moreover, high doses of mistletoe have been shown in vitro to inhibit CYP3A4 activity. Consequently, mistletoe could positively affect the metabolism of letrozole by increasing the bioavailability of the drug, but also have a negative effect by increasing the adverse effects of the drug itself [44–47]. Nux-vomica extracts are usually used in the traditional Chinese medicine for their effects on the nervous system analgesic and anti-inflammatory activity. Preclinical studies also suggest an anticancer effect in breast cancer cells; unfortunately, at high doses it can be toxic due to poisonous compounds present in its composition such as strychnine, brucine, and loganine [48, 49]. Furthermore, Nux-vomica extracts may act as inhibitors of CYP2C, CYP3A, and CYP1A2 enzymatic activity [50, 51].

The second example is a 47-year-old woman with metastatic breast cancer. In the questionnaire, she stated that she was taking AHCC (active hexose correlated compound), a shiitake mushroom extract, which the patient used to alleviate the side effects of paclitaxel and bevacizumab. The antioxidant and immunostimulant properties of AHCC have been recently described, and the use of AHCC appears to be protective against the side effects of chemotherapy. In addition, AHCC is also a potential inducer of aromatase, a key enzyme of hormone-sensitive breast cancer growth [52–54]. Finally, in patients showing the variant V158M genotype of COMT (catechol-o-methyltransferase, estrogens inactivating enzyme involved in their metabolism), AHCC reduces the effects of aromatase inhibitors as in the case of the use of letrozole [55].

5. Conclusions

According to the scientific literature, the results of our study have confirmed that cancer patients increasingly turn to TCIM treatments after the diagnosis with the aim to reduce symptoms and also the negative effects of anticancer treatments, with the hope of obtaining an improvement in the quality of life. However, the survey has highlighted a frequent lack of correspondence between the benefits expected by patients from specific treatments and their actual, evidence-based properties, emphasizing the potential risks coming from TCIM use without consulting healthcare providers, particularly if taken during conventional therapy. The importance of this study is to point out the impelling need to provide reliable and scientifically validated information on the use of TCIM, not only on their biological and pharmacological properties and on their potential benefits, but also on the risks of an incorrect association with anticancer drugs. The importance of this information also has economic implications, considering the economic burden for public health systems to diagnose and treat this pathology. It is therefore understandable that a therapy that is not optimized for a patient, because it includes ancillary substances that may have conflicting effects, may also result in economic harm to the patient and to the health care economy.

Data Availability

Data are available on request due to restrictions of privacy or ethical issues. The data presented in this study are not publicly available due to privacy protection of the patients that answered the questionnaire. Under specific requests by the editor or reviewers, raw data can be provided by Francesco Lozupone (e-mail: francesco.lozupone@iss.it)

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

F.L., M.B., A.G., D.P., and F.D.L. were responsible for conceptualization and methodology; D.C., A.P., and F.T. were responsible for software; F.L., C.V., M.B., and S.M. performed formal analysis; FL, A.G., C.V., and M.C. performed data analysis; F.L., M.C., S.M., and M.B. prepared the original draft; F.L., S.M., M.C., L.D.C, and F.D.L. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

The authors acknowledge all the participants who answered the questionnaire for their contribution to this study. This research did not receive specific external funding, but was performed with institutional funds from the Italian National Institute of Health.

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] Global Burden of Disease Cancer Collaboration, “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis
for the global burden of disease study," JAMA Oncology, vol. 5, no. 12, pp. 1749–1768, 2019.

[3] L. Falzone, S. Salomone, and M. Libra, "Evolution of cancer pharmacological treatments at the turn of the third millennium," Frontiers in Pharmacology, vol. 9, p. 1300, 2018.

[4] A. Pearce, M. Haas, R. Viney et al., "Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study," PLoS One, vol. 12, no. 10, Article ID e0184360, 2017.

[5] M. J. Hassett, A. J. O’Malley, J. R. Pakes, J. P. Newhouse, and C. C. Earle, "Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer," Journal of the National Cancer Institute: Journal of the National Cancer Institute, vol. 98, no. 16, pp. 1108–1117, 2006.

[6] K. Arthur, J. C. Belliard, S. B. Hardin, K. Knecht, C. S. Chen, and S. Montgomery, "Practices, attitudes, and beliefs associated with complementary and alternative medicine (CAM) use among cancer patients," Integrative Cancer Therapies, vol. 11, no. 3, pp. 232–242, 2012.

[7] C. A. Buckner, R. M. Lafortune, J. A. Denommée, J. M. Caswell, and D. A. Want, "Complementary and alternative medicine use in patients before and after a cancer diagnosis," Current Oncology, vol. 25, no. 4, pp. 275–281, 2018.

[8] M. Horneber, G. Bueschel, G. Dennert, D. Less, E. Ritter, and M. Zwahlen, "How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis," Integrative Cancer Therapies, vol. 11, no. 3, pp. 187–203, 2012.

[9] N. Vapiwala, R. Mick, M. K. Hampshire, J. M. Metz, and A. S. DeNittis, "Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis," The Cancer Journal, vol. 12, pp. 467–474, 2006.

[10] https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine#tab=tab_1.

[11] https://www.ncbi.nlm.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name?.

[12] D. Agajándzú, T. Ö. Şahin, B. Yılmaz, K. D. Ekenci, D. Özer, and R. Capasso, "Cruciferous vegetables and their bioactive metabolites: from prevention to novel therapies of colorectal cancer," Evidence-based Complementary and Alternative Medicine: eCAM, vol. 2022, Article ID 1534083, 20 pages, 2022.

[13] J. Fernández, B. Silván, R. Entrialgo-Cadierno et al., "Anti-proliferative and palliative activity of flavonoids in colorectal cancer," Biomedicine & Pharmacotherapy, vol. 143, Article ID 112341, 2021.

[14] M. R. Islam, F. Islam, M. H. Nafady et al., "Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint," Molecules, vol. 27, no. 7, p. 2165, 2022.

[15] E. K. Akkol, I. I. Tath, G. S. Karotoprak et al., "Is emodin with anticancer effects completely innocent? Two sides of the coin," Cancers, vol. 13, no. 11, p. 2733, 2021.

[16] J. d. N. Silva, N. B. N. Monção, R. R. S. de Farias et al., "Toxicological, chemopreventive, and cytotoxic potentialities of rare vegetal species and supporting findings for the Brazilian Unified Health System (SUS)," Journal of Toxicology and Environmental Health, Part A, vol. 83, no. 13–14, pp. 525–545, 2020.

[17] E. R. Sauter, "Cancer prevention and treatment using combination therapy with natural compounds," Expert Review of Clinical Pharmacology, vol. 13, no. 3, pp. 265–285, 2020.

[18] S. R. Lin, C. H. Chang, C. F. Hsu et al., "Natural compounds as potential adjuvants to cancer therapy: preclinical evidence," British Journal of Pharmacology, vol. 177, no. 6, pp. 1409–1423, 2020.

[19] P. E. Harris, K. L. Cooper, C. Relton, and K. J. Thomas, "Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update," International Journal of Clinical Practice, vol. 66, no. 10, pp. 924–939, 2012.

[20] M. Berretta, C. D. Pepa, P. Tralongo et al., "Use of Complementary and Alternative Medicine (CAM) in cancer patients: an Italian multicenter survey," Oncotarget, vol. 8, no. 15, pp. 24401–24414, 2017.

[21] L. M. Kemppainen, T. T. Kemppainen, J. A. Reippainen, S. T. Salmenniemi, and P. H. Vuolanto, "Use of complementary and alternative medicine in Europe: health-related and sociodemographic determinants," Scandinavian Journal of Public Health, vol. 46, no. 4, pp. 448–455, 2018.

[22] J. S. McLay, D. Stewart, J. George, C. Roare, and S. D. Heys, "Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions?" European Journal of Clinical Pharmacology, vol. 68, no. 5, pp. 811–819, 2012.

[23] W. E. Haefeli and A. Carls, "Drug interactions with phytotherapeutics in oncology," Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 3, pp. 359–377, 2014.

[24] I. Meijerman, J. H. Beijnen, and J. H. M. Schellens, "Herb-drug interactions in oncology: focus on mechanisms of induction," The Oncologist, vol. 11, no. 7, pp. 742–752, 2006.

[25] P. Posadzki, L. Watson, and E. Ernst, "Herb-drug interactions: an overview of systematic reviews," British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 603–618, 2013.

[26] M. Steie, C. Delmar, B. Nørgaard, and L. H. Jensen, "Impact of open dialogue about complementary alternative medicine-A phase II randomized controlled trial," Cancers, vol. 14, no. 4, p. 952, 2022.

[27] A. L. Claret, M. Boiteux-Jurain, E. Curtit et al., "Interaction between phytotherapy and oral anticancer agents: prospective study and literature review," Medical Oncology, vol. 36, no. 5, 2019.

[28] B. J. Bernstein and T. Grasso, "Prevalence of complementary and alternative medicine use in cancer patients," Oncology, vol. 15, no. 10, 2001.

[29] R. Behzadmehr, N. Dastyar, M. P. Moghadam, M. Abavasi, and M. Moradi, "Effect of complementary and alternative medicine interventions on cancer related pain among breast cancer patients: a systematic review," Complementary Therapies in Medicine, vol. 49, Article ID 102318, 2020.

[30] S. A. Dufter, J. Hübner, E. Ahmadi, and B. Zomorodbakhsch, "Treats of cancer patients and CAM usage," Journal of Cancer Research and Clinical Oncology, vol. 147, no. 12, pp. 3685–3692, 2021.

[31] M. A. Richardson, T. Sanders, J. L. Palmer, A. Greisinger, and S. E. Singletary, "Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology," Journal of Clinical Oncology, vol. 18, no. 13, pp. 2505–2514, 2000.

[32] J. S. Yates, K. M. Mustian, G. R. Morrow et al., "Prevalence of complementary and alternative medicine use in cancer patients during treatment," Supportive Care in Cancer, vol. 13, no. 10, pp. 806–811, 2005.

[33] J. A. Scott, N. Kearney, S. Hummerston, and A. Molassiotis, "Use of complementary and alternative medicine in patients with cancer: a UK survey," European Journal of Oncology Nursing, vol. 9, no. 2, pp. 131–137, 2005.
Evidence-Based Complementary and Alternative Medicine

[34] R. Pihlak, R. Liivand, O. Treln et al., “Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling,” European Journal of Cancer Care, vol. 23, no. 2, pp. 249–254, 2014.

[35] K. Wode, R. Henrikkson, L. Sharp, A. Stoltenberg, and J. Hök Nordberg, ‘Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study,” BMC Complementary and Alternative Medicine, vol. 19, no. 1, p. 62, 2019.

[36] S. A. Murray, M. Kendall, K. Boyd, and A. Sheikh, “Illness trajectories and palliative care,” BMJ, vol. 330, pp. 1007–1011, 2005.

[37] P. Carlo, “Cancer Forum,” Cancer Forum, vol. 35, pp. 21–39, 2011.

[38] M. J. Verhoef, L. Trojan, G. D. Armitage, L. Carlson, and R. J. Hillsden, “Complementary therapies for cancer patients: assessing information use and needs,” Chronic Diseases in Canada, vol. 29, no. 2, pp. 80–88, 2009.

[39] S. Wanwimolruk and V. Prachayasittikul, “Cytochrome P450 enzyme mediated herbal drug interactions (Part 1),” EXCLI Journal, vol. 13, pp. 347–391, 2014.

[40] S. Wanwimolruk and V. Prachayasittikul, “Cytochrome P450 enzyme mediated herbal drug interactions (Part 1),” EXCLI Journal, pp. 347–391, 2014.

[41] S. Mitra, M. S. Lami, A. Ghosh et al., “Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications?” Cancers, vol. 14, no. 3, p. 759, 2022.

[42] W. Tröger, Z. Zdrale, N. Stanković, and M. Matijašević, “Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone,” Breast Cancer: Basic and Clinical Research, vol. 6, Article ID BCBCR.S10558, 2012.

[43] V. F. Semiglazov, V. V. Stepula, A. Dudov, J. Schnitker, and U. Mengs, “Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial,” Anticancer Research, vol. 26, pp. 1519–1529, 2006.

[44] S. Engdal and O. G. Nilsen, “In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients,” Phytotherapy Research, vol. 23, no. 7, pp. 906–912, 2009.

[45] M. Schink and O. Dehus, “Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities,” BMC Complementary and Alternative Medicine, vol. 17, no. 1, p. 521, 2017.

[46] P. G. Werthmann, R. Huber, and G. S. Kienle, “Durable clinical remission of a skull metastasis under intralesional Viscum album extract therapy: case report,” Head & Neck, vol. 40, no. 7, pp. E77–E81, 2018.

[47] U. Weissenstein, M. Kunz, K. Urech, and S. Baumgartner, “Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro,” BMC Complementary and Alternative Medicine, vol. 14, no. 1, p. 6, 2014.

[48] O. A. Eldahshan and M. M. Abdel-Daim, “Phytochemical study, cytotoxic, analgesic, antipyretic and anti-inflammatory activities of Strychnos nux-vomica,” Cytotechnology, vol. 67, no. 5, pp. 831–844, 2015.

[49] C. C. Anajwala, R. M. Patel, S. L. Dakhara, and J. K. Jariwala, “In vitro cytotoxicity study of agave americana, strychnos nuxvomica and areca catechu extracts using mcf-7 cell line,” Journal of Advanced Pharmaceutical Technology & Research, vol. 1, no. 2, pp. 245–252, 2010.

[50] Q. Gao, J. J. Wang, F. m. Han, and Y. Chen, “Effect of strychnine hydrochloride on liver cytochrome P450 mRNA expression and monoxygenase activities in rat,” Acta Pharmacologica Sinica B, vol. 1, no. 2, pp. 121–128, 2011.

[51] P. p. Xing, W. h. Wu, P. Du, F. m. Han, and Y. Chen, “Effects of brucine combined with glycyrrhetinic acid or liquiritin on rat hepatic cytochrome P450 activities in vivo,” Yao Xue Xue Bao, vol. 46, no. 5, pp. 573–580, 2011.

[52] T. Ito, H. Urushima, M. Sakaue et al., “Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy--the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy,” Nutrition and Cancer, vol. 66, no. 3, pp. 377–382, 2014.

[53] S. Hangai, S. Iwase, T. Kawaguchi et al., “Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study,” Journal of Alternative & Complementary Medicine, vol. 19, no. 11, pp. 905–910, 2013.

[54] S. Suenaga, Y. Kuramitsu, S. Kaino et al., “Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine,” Anticancer Research, vol. 34, no. 1, pp. 141–146, 2014.

[55] L. Mathew, A. Gaikwad, A. Gonzalez, E. K. Nugent, and J. A. Smith, “Evaluation of active hexose correlated compound (AHCC) in combination with anticancer hormones in orthotopic breast cancer models,” Integrative Cancer Therapies, vol. 16, no. 3, pp. 300–307, 2017.